Graig Suvannavejh
Stock Analyst at Mizuho
(3.36)
# 994
Out of 4,964 analysts
157
Total ratings
50.83%
Success rate
2.32%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Graig Suvannavejh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintains: Outperform | $130 → $165 | $134.97 | +22.25% | 11 | Aug 13, 2025 | |
| ALEC Alector | Upgrades: Outperform | $2.5 → $3.5 | $2.39 | +46.44% | 5 | Jul 28, 2025 | |
| NMRA Neumora Therapeutics | Maintains: Outperform | $4 → $5 | $1.76 | +184.09% | 2 | Jul 16, 2025 | |
| ADVM Adverum Biotechnologies | Maintains: Outperform | $16 → $12 | $3.03 | +296.04% | 5 | Jun 26, 2025 | |
| ADAP Adaptimmune Therapeutics | Downgrades: Neutral | $1.5 → $0.5 | $0.07 | +625.69% | 3 | Jun 26, 2025 | |
| IMRX Immuneering | Maintains: Outperform | $8 → $10 | $5.60 | +78.57% | 2 | Jun 18, 2025 | |
| CRVS Corvus Pharmaceuticals | Maintains: Outperform | $12 → $11 | $5.41 | +103.33% | 3 | May 20, 2025 | |
| EYPT EyePoint Pharmaceuticals | Maintains: Outperform | $30 → $26 | $11.60 | +124.14% | 5 | May 16, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $44 → $48 | $37.97 | +26.42% | 18 | May 15, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Neutral | $30 → $20 | $28.05 | -28.70% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7 → $8 | $9.42 | -15.07% | 7 | May 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $33 | $32.24 | +2.36% | 8 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $212 → $216 | $121.75 | +77.41% | 21 | Mar 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $7 → $7.6 | $1.57 | +384.08% | 1 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $74 | $9.90 | +647.47% | 1 | Sep 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $5 → $0.5 | $0.39 | +27.88% | 3 | Sep 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $44 → $49 | $72.81 | -32.70% | 6 | Jul 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $24.93 | +100.56% | 1 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $14 → $16 | $5.26 | +204.18% | 3 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $17 → $10 | $7.07 | +41.44% | 5 | Nov 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $64 | $4.10 | +1,460.98% | 8 | Aug 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $17 → $1 | $3.85 | -74.03% | 5 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $35 | $104.23 | -66.42% | 5 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $9 → $8 | $8.97 | -10.81% | 6 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $71 → $57 | $37.35 | +52.61% | 2 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $8 → $5 | $28.96 | -82.73% | 4 | Apr 19, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $8.84 | +284.62% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $28 | $5.64 | +396.45% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $31 | $14.65 | +111.60% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Sell | $19 | $2.01 | +845.27% | 1 | Mar 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $4.75 | $2.08 | +128.37% | 1 | Nov 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $36 | $15.49 | +132.41% | 2 | Nov 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | n/a | $32.42 | - | 1 | Oct 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $37 | $1.29 | +2,768.22% | 1 | Oct 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $128 | $126.13 | +1.48% | 1 | Sep 14, 2020 |
Insmed
Aug 13, 2025
Maintains: Outperform
Price Target: $130 → $165
Current: $134.97
Upside: +22.25%
Alector
Jul 28, 2025
Upgrades: Outperform
Price Target: $2.5 → $3.5
Current: $2.39
Upside: +46.44%
Neumora Therapeutics
Jul 16, 2025
Maintains: Outperform
Price Target: $4 → $5
Current: $1.76
Upside: +184.09%
Adverum Biotechnologies
Jun 26, 2025
Maintains: Outperform
Price Target: $16 → $12
Current: $3.03
Upside: +296.04%
Adaptimmune Therapeutics
Jun 26, 2025
Downgrades: Neutral
Price Target: $1.5 → $0.5
Current: $0.07
Upside: +625.69%
Immuneering
Jun 18, 2025
Maintains: Outperform
Price Target: $8 → $10
Current: $5.60
Upside: +78.57%
Corvus Pharmaceuticals
May 20, 2025
Maintains: Outperform
Price Target: $12 → $11
Current: $5.41
Upside: +103.33%
EyePoint Pharmaceuticals
May 16, 2025
Maintains: Outperform
Price Target: $30 → $26
Current: $11.60
Upside: +124.14%
Harmony Biosciences Holdings
May 15, 2025
Maintains: Outperform
Price Target: $44 → $48
Current: $37.97
Upside: +26.42%
Apellis Pharmaceuticals
May 14, 2025
Maintains: Neutral
Price Target: $30 → $20
Current: $28.05
Upside: -28.70%
May 14, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $9.42
Upside: -15.07%
Apr 7, 2025
Maintains: Neutral
Price Target: $38 → $33
Current: $32.24
Upside: +2.36%
Mar 27, 2025
Maintains: Outperform
Price Target: $212 → $216
Current: $121.75
Upside: +77.41%
Nov 18, 2024
Upgrades: Buy
Price Target: $7 → $7.6
Current: $1.57
Upside: +384.08%
Sep 20, 2024
Reiterates: Outperform
Price Target: $74
Current: $9.90
Upside: +647.47%
Sep 19, 2024
Downgrades: Neutral
Price Target: $5 → $0.5
Current: $0.39
Upside: +27.88%
Jul 22, 2024
Maintains: Neutral
Price Target: $44 → $49
Current: $72.81
Upside: -32.70%
Jul 8, 2024
Initiates: Outperform
Price Target: $50
Current: $24.93
Upside: +100.56%
May 16, 2024
Maintains: Buy
Price Target: $14 → $16
Current: $5.26
Upside: +204.18%
Nov 27, 2023
Maintains: Buy
Price Target: $17 → $10
Current: $7.07
Upside: +41.44%
Aug 23, 2023
Reiterates: Neutral
Price Target: $64
Current: $4.10
Upside: +1,460.98%
Jun 5, 2023
Downgrades: Neutral
Price Target: $17 → $1
Current: $3.85
Upside: -74.03%
Nov 10, 2022
Maintains: Buy
Price Target: $31 → $35
Current: $104.23
Upside: -66.42%
Nov 10, 2022
Maintains: Neutral
Price Target: $9 → $8
Current: $8.97
Upside: -10.81%
May 24, 2022
Maintains: Buy
Price Target: $71 → $57
Current: $37.35
Upside: +52.61%
Apr 19, 2022
Maintains: Sell
Price Target: $8 → $5
Current: $28.96
Upside: -82.73%
Jun 1, 2021
Initiates: Buy
Price Target: $34
Current: $8.84
Upside: +284.62%
Apr 20, 2021
Initiates: Neutral
Price Target: $28
Current: $5.64
Upside: +396.45%
Apr 19, 2021
Initiates: Neutral
Price Target: $31
Current: $14.65
Upside: +111.60%
Mar 2, 2021
Initiates: Sell
Price Target: $19
Current: $2.01
Upside: +845.27%
Nov 24, 2020
Initiates: Neutral
Price Target: $4.75
Current: $2.08
Upside: +128.37%
Nov 9, 2020
Upgrades: Buy
Price Target: $36
Current: $15.49
Upside: +132.41%
Oct 21, 2020
Downgrades: Sell
Price Target: n/a
Current: $32.42
Upside: -
Oct 20, 2020
Initiates: Neutral
Price Target: $37
Current: $1.29
Upside: +2,768.22%
Sep 14, 2020
Downgrades: Sell
Price Target: $128
Current: $126.13
Upside: +1.48%